JBS SCIENCE - Key Persons
Job Titles:
- Member of the Board
- President & CEO, Richen - Force Science and Technology Ltd., China
Job Titles:
- Member of the Board
- CEO & Founder, Molecular Targeting Technologies, Inc
Dr. Di Chen obtained his PhD in the Department of Statistics at North Carolina State University, Raleigh, NC and his post-doctoral fellow training in the School of Industrial and System Engineering at Georgia Institute of Technology. Since then, Dr. Chen has been working as a Biostatistician in the industries. With more than 10 years of experience as a biostatistician and more than 5 years of experience focusing on the field of cancer biomarker study design, data analysis for biomarker discovery, and validation to bringing promising biomarkers to clinical trials, Dr. Chen foresees the potential of transrenal DNA technology and cancer genetics to transform how cancer can be diagnosed and managed at the personal level and joins JBS Science Inc. as a consultant and a member of the scientific advisory committee to provide guidance in study design, sample size calculation, data analysis, and interpretation.
Job Titles:
- Member of the Board
- Co - Founder, Chief Executive Officer, Chief Medical Officer & Chair of the Board
Dr. Frank W. Song received his MD. from Shanghai Medical University, China and PhD. in Pharmacology and Molecular biology from the University of South Alabama. He was trained as a hematology and oncology fellow at The Temple/Fox Chase Cancer Center program and is a board-certified hematologist and medical oncologist. In addition to his Ph.D. training, he also had his post-doctoral research training at Dr William Mason's lab at Fox Chase Cancer Center focusing on Hepatitis B and liver cancer. Currently, he is a practicing medical oncologist, has been an on-site PI for over 100 clinical trials, and is the hospital cancer center medical director. Dr. Song recognizes the limited treatment options and dismal prognosis when cancer is diagnosed in its late stages. He founded JBS Science, Inc to develop novel non-invasive diagnostic technologies of urine DNA tests for detecting cancer-associated, genetic alterations for cancer screening and treatment. His mission is to detect cancer earlier at curative stages and improve the survival rate by treating each unique cancer patient based on DNA genetic information.
Job Titles:
- Chairman & Founder, JunXin Medical LLC
Job Titles:
- Chief Operating Officer
- Member of the Board
- COO, Genesis Biotech Group
Dr. Adelson (Chief Operating Officer, Genesis Biotechnology Group) is one of the members in the Scientific Advisory Board and has been providing advice to the assay development. He has extensive expertise in the development and commercialization of quality diagnostic tests through CAP-accredited CLIA laboratory in Medical Diagnostic Laboratories in Hamilton, New Jersey. His team has developed a large number of PCR-based diagnostic assays for the detection and management of infectious diseases and cancer screening and offers these services to thousands of physicians across the United States, as well as internationally. He will provide assistance in product development including generating industry standard operating procedures, as well as assisting in future FDA submissions. He has sat on the Editorial Board for the Journal of Clinical Microbiology and for Diagnostic Microbiology and Infectious Disease, and is currently a member of the American Society for Microbiology, the International Organization for Mycoplasmology, the Thomas Jefferson University Biotechnology Program Advisory Committee, and the Association for Molecular Pathology. Dr. Adelson holds a certificate of qualification from the New York State Department of Health and has published close to fifty articles in the field of biotechnology.
Dr. Lin leads clinical, development, and discovery research operations. Dr. Lin has over a decade of experience in developing PCR-based assays for detecting circulating tumor-related DNA (ctDNA) modifications for cancer diagnostics and monitoring. During her time as VP of Technology Development, she focused on optimizing and robustly implementing numerous HCC biomarkers that are part the JBS HCC test, including a novel biomarker of analyzing HBV DNA integration sites and targeted genes in urine of patients with HBV-related liver disease that is derived from her PhD thesis. Prior to JBS, Dr. Lin was a Molecular Oncology Postdoctoral Research Fellow at John Wayne Cancer Institute. Dr. Lin holds a PhD in Microbiology and Immunology from Drexel University College of Medicine.
Job Titles:
- Co - Founder
- Member of the Board
- Co - Founder, JBS Science Inc, Professor, Translational Medical Science, the Baruch S. Blumberg Institute
Job Titles:
- Interim Chief Scientific Officer